# Petrelintide Beginner's Guide: Roche/Zealand's Weekly Amylin Analog
> Note: PeptIQ is not a medical provider. Petrelintide is investigational. Educational content only.
Petrelintide is a once-weekly long-acting human amylin analog from Roche/Genentech and Zealand Pharma. If eloralintide is Lilly's amylin headline, petrelintide is the Roche/Zealand counterpart — with a Phase 2 story that emphasizes meaningful loss + strong tolerability commentary.
What Beginners Should Know
- Pathway: amylin satiety — related to, not identical with, GLP-1
- Cadence: once-weekly subcutaneous in ZUPREME-1
- Design: five dose arms, escalation about every 4 weeks
- Signal: up to ~10.7% mean weight loss at 42 weeks vs ~1.7% placebo in public summaries
- Next: ZUPREME-2 in obesity + type 2 diabetes; combo exploration with CT-388
Exact milligrams for every arm may remain partially masked until full congress tables — do not invent them.
How It Differs From Eloralintide and Cagrilintide
| Petrelintide | Eloralintide | Cagrilintide | |
|---|---|---|---|
| Sponsor lane | Roche / Zealand | Lilly | Novo (CagriSema) |
| Public dose clarity | Five weekly arms (mg table pending full release) | 1–9 mg Phase 2 published | 2.4 mg in CagriSema pairing |
| Narrative emphasis | Tolerability + solid Phase 2 loss | Higher Phase 2 efficacy ceiling | Combo with semaglutide |
What to Track
Weekly injection day, escalation week, GI / early fullness scores, protein, lifting, waist, average weight.
FAQ
Q: Is petrelintide a GLP-1?
A: No — amylin analog.
Q: Is it available to buy?
A: Treat as investigational clinical pipeline, not a research-peptide shopping item.
Bottom Line
Petrelintide is the weekly amylin beginner name beside eloralintide: ZUPREME-1 double-digit loss, tolerability-forward messaging, and a Roche stack that may eventually pair with CT-388.
Download PeptIQ to track amylin-pathway protocols with symptom scores.
Educational content only. Not medical advice.
